EyePoint Pharmaceuticals Enters Material Definitive Agreement
Ticker: EYPT · Form: 8-K · Filed: Oct 31, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $11.00, $151.1 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
EyePoint Pharma just signed a big deal, filing an 8-K on 10/28/24.
AI Summary
EyePoint Pharmaceuticals, Inc. announced on October 28, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as pSivida Corp. and pSivida LTD, is incorporated in Delaware and headquartered in Watertown, MA.
Why It Matters
This filing indicates a significant new contract or partnership for EyePoint Pharmaceuticals, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- October 28, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by EyePoint Pharmaceuticals?
The filing states that EyePoint Pharmaceuticals, Inc. entered into a Material Definitive Agreement on October 28, 2024, but the specific details of the agreement are not provided in this document.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 28, 2024.
What were the former names of EyePoint Pharmaceuticals, Inc.?
EyePoint Pharmaceuticals, Inc. was formerly known as pSivida Corp. and pSivida LTD.
Where is EyePoint Pharmaceuticals, Inc. headquartered?
EyePoint Pharmaceuticals, Inc. is headquartered at 480 Pleasant Street, Suite B300, Watertown, MA 02472.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed as a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,148 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2024-10-31 16:16:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Indi
- $11.00 — blic for the Shares in the Offering was $11.00 per Share. In addition, under the terms
- $151.1 m — e additional shares, were approximately $151.1 million, after deducting underwriting dis
Filing Documents
- d904414d8k.htm (8-K) — 31KB
- d904414dex11.htm (EX-1.1) — 229KB
- d904414dex51.htm (EX-5.1) — 9KB
- d904414dex991.htm (EX-99.1) — 13KB
- d904414dex992.htm (EX-99.2) — 14KB
- d904414dex993.htm (EX-99.3) — 14KB
- g904414eyepoint.jpg (GRAPHIC) — 6KB
- g904414g1031080912856.jpg (GRAPHIC) — 2KB
- g904414g1031085132661.jpg (GRAPHIC) — 4KB
- 0001193125-24-248694.txt ( ) — 533KB
- eypt-20241028.xsd (EX-101.SCH) — 3KB
- eypt-20241028_lab.xml (EX-101.LAB) — 17KB
- eypt-20241028_pre.xml (EX-101.PRE) — 11KB
- d904414d8k_htm.xml (XML) — 3KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the Offering and the use of proceeds from the Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions, as well as other risks detailed from time to in the Company's Securities and Exchange Commission filings, including in its Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, its Current Reports on Form 8-K and the prospectus supplement dated October 29, 2024 relating to the Offering. These documents contain important factors that could cause actual results to differ from current expectations and from forward-looking statements contained in this Current Report on Form 8-K. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K. Item8.01. Other Events. The Company issued press releases announcing the launch, pricing and closing of the Offering on October 28, 2024, October 29, 2024 and October 31, respectively. Copies of these press releases are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are each incorporated herein by reference. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 1.1 Underwriting Agreement, dated October 29, 2024, by and between EyePoint Pharmaceuticals, Inc. and J.P. Morgan Securities LLC 5.1 Opinion of Hogan Lovells US LLP 23.1 Consent of Hogan Lovells US LLP (contained in Exhibit 5.1) 99.1 Press Release issued by the Company announcing the launch of the Offering on October 28, 2024 99.2 Press Release issued by the Company announcing the pricing of the Offering on October 29, 2024 99.3 Press Release issued by the Company announcing the closing of the Offering on October 31, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: October 31, 2024 /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer